ArticleGynecologic oncology2008
MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer.
Article in Gynecologic oncology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. It is linked to 4 registered trials, which are not on this map. Cited by 1,197 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Feasibility Study of Circulating microRNAs as Disease Markers in Pediatric Cancers
Collection of Blood and Cerebrospinal Fluid for Pediatric Brain Tumor Research
A Longitudinal Study of Biomarkers in Pediatric Patients With Central Nervous System Tumors
MicroRNAs as Disease Markers for Central Nervous System Tumors in Patients With Neurofibromatosis Type 1
Who cites it
1,197 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Extracellular vesicle biomarkers in circulation for colorectal cancer detection: a systematic review and meta-analysis.BMC cancer · 2024Pooled it
- Advancements and trends in exosome research in lung cancer from a bibliometric analysis (2004-2023).Frontiers in oncology · 2024Pooled it
- Liquid Biopsy in Endometriosis: A Systematic Review.International journal of molecular sciences · 2023Pooled it
- The current trend of exosome in epithelial ovarian cancer studies: A bibliometric review.Frontiers in pharmacology · 2023Pooled it
- Progress in research on the role of exosomal miRNAs in the diagnosis and treatment of cardiovascular diseases.Frontiers in genetics · 2022Pooled it
- Meta-analysis of the diagnostic value of exosomal miR-21 as a biomarker for the prediction of cancer.Journal of clinical laboratory analysis · 2021Pooled it
- Recent advancements in exosomal content analysis: the future of liquid biopsy.Molecular biology reports · 2026Review
- Performance of AI Tools in Citing Retracted Literature : Content Analysis.Journal of medical Internet research · 2026Article
- Insights into extracellular vesicle-based platforms on the way to cancer treatment.Journal of translational medicine · 2025Review
- Tumor exosomal miR-221-3p induces glycolysis through the LIFR/GLUT1 pathway to destroy the cerebral vascular endothelial cell barrier and promote breast cancer brain metastasis.Journal of translational medicine · 2025Article
- Advances in liquid biopsy for bone and soft-tissue sarcomas.International journal of clinical oncology · 2025Review
- An axon guidance-related microRNA panel identifies perivascular plexus local recurrence following curative surgery in patients with pancreatic cancer.Journal of gastroenterology · 2025Article
- Self-modulating therapeutic platform using engineered miRNA-responsive oligonucleotides.Nano convergence · 2025Article
- Detection of KRAS Mutations Using Extracellular Vesicle DNA in Colorectal Cancer Patients.Cancer science · 2025Observational
- MircoRNAs predict and modulate responses to chemotherapy in leukemic patients.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Effects of Clinical Covariates on Serum miRNA Expression among Women without Ovarian Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Article
- Therapeutic Chemoresistance in Ovarian Cancer: Emerging Hallmarks, Signaling Mechanisms and Alternative Pathways.Current medicinal chemistry · 2025Review
- Exosomal proteins: new targets for early diagnosis and treatment of cancer.Frontiers in immunology · 2025Review
- Tumor-derived vesicles in immune modulation: focus on signaling pathways.Frontiers in immunology · 2025Review
- Blood-based biomarkers in pancreatic ductal adenocarcinoma: developments over the last decade and what holds for the future- a review.Frontiers in oncology · 2025Review
1,137 more citing papers are in PubMed but not listed here.
Corrections and comments
- Correction · 2009-10-07Error in Image · Updated to Retraction · · Douglas Taylor has ORI finding of misconduct: https://ori.hhs.gov/content/case-summary-taylor-douglas-d?s=03
- Retraction · 2023-07-20Falsification/Fabrication of Data · Investigation by Company/Institution · Investigation by ORI · Misconduct - Official Investigation(s) and/or Finding(s) · Misconduct by Author · Plagiarism of Data · Upgrade/Update of Prior Notice(s) · · Douglas Taylor has ORI finding of misconduct: https://ori.hhs.gov/content/case-summary-taylor-douglas-d?s=03
- Commented on by
- Commented on by
- Erratum issued
- Retracted
Authors and funding
2 authors.
Funding
Abstract
objectivesMost ovarian cancer patients are diagnosed at an advanced stage (67%) and prospects for significant improvement in survival reside in early diagnosis. While expression patterns of a recently identified biomarker family, microRNA, appear to be characteristic of tumor type and developmental origin, microRNA profiling has been limited to tissue specimens. Tumors actively release exosomes into the peripheral circulation and we now demonstrate the association of microRNAs with circulating tumor-derived exosomes.
methodsCirculating tumor exosomes were isolated using a modified MACS procedure with anti-EpCAM. Initially, microRNA profiles of ovarian tumors were compared to those of tumor exosomes isolated from the same patients. Levels of 8 microRNAs (miR-21, miR-141, miR-200a, miR-200c, miR-200b, miR-203, miR-205 and miR-214) previously demonstrated as diagnostic, were compared in exosomes isolated from sera specimens of women with benign disease and various stages of ovarian cancer.
resultsMicroRNA from ovarian tumor cells and exosomes from the same patients were positive for 218 of 467 mature microRNAs analyzed. The levels of the 8 specific microRNAs were similar between cellular and exosomal microRNAs (exhibiting correlations from 0.71 to 0.90). While EpCAM-positive exosomes were detectable in both patients with benign ovarian disease and ovarian cancer, exosomal microRNA from ovarian cancer patients exhibited similar profiles, which were significantly distinct from profiles observed in benign disease. Exosomal microRNA could not be detected in normal controls.
conclusionsThese results suggest that microRNA profiling of circulating tumor exosomes could potentially be used as surrogate diagnostic markers for biopsy profiling, extending its utility to screening asymptomatic populations.
Indexed as
Identifiers
18589210What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.